Valuation: Ono Pharmaceutical Co., Ltd.

Market Cap 1,171B 7.15B 6.28B 5.84B 5.38B 10.08B 683B 10.25B 69.34B 27.14B 339B 26.85B 26.27B P/E 2027 *
16x
P/E 2028 * 18.2x
Enterprise Value 972B 5.94B 5.21B 4.85B 4.46B 8.36B 567B 8.51B 57.54B 22.52B 281B 22.28B 21.8B EV / Sales 2027 *
2.14x
EV / Sales 2028 * 2.14x
Free-Float
80.98%
Yield 2027 *
3.24%
Yield 2028 * 3.21%
07-28 Ono Pharmaceutical Co., Ltd. Partners with Phylo, Inc. to Embed Agentic AI with Every Discovery Scientist CI
06-19 Mizuho Securities Upgrades Ono Pharmaceutical to Buy from Neutral; Price Target is 3,200 Yen MT
06-18 Ono Pharmaceutical to Dispose of 47 Million Yen Treasury Shares Under Stock Compensation Plan MT
06-01 Ono Pharmaceutical Co., Ltd. Announces Oral Presentation Of New Data From The Phase 2 Clinical Study Of ONO-4578 In Certain Gastric Cancers At The ASCO 2026 Annual Meeting CI
05-29 Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,500 Yen From 1,750 Yen, Keeps at Hold MT
05-08 Ono Pharmaceutical's Attributable Profit Jumps 39% in Fiscal Year 2025 MT
05-07 Ono Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-07 Ono Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-07 Ono Pharmaceutical Co., Ltd. Proposes Year End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 19, 2026 and Provides Dividend Forecasts for the Second Quarter of Year Ending March 31, 2027 and Fiscal Year Ending March 31, 2027 CI
04-22 Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
1 day+3.08%
1 week+3.94%
Current month+4.33%
1 month+4.79%
3 months+7.74%
6 months+9.95%
Current year+14.68%
1 week 2,378
Extreme 2378
2,514.5
1 month 2,336
Extreme 2336
2,514.5
Current year 2,114.5
Extreme 2114.5
2,674.5
1 year 1,596
Extreme 1596
2,674.5
3 years 1,474
Extreme 1474
2,966.5
5 years 1,474
Extreme 1474
3,990
10 years 1,474
Extreme 1474
3,990
Manager TitleAgeSince
Chief Executive Officer 67 2024-03-31
Director of Finance/CFO - 2026-03-31
President 57 2024-03-31
Director TitleAgeSince
Chairman 67 2024-03-31
Director/Board Member 57 2020-05-31
Director/Board Member 76 2018-06-25
Change 5-day change 1-year change 3-year change Capi.($)
+3.08%+3.94%+50.54%-4.41% 6.94B
+0.67%+2.41%+16.33%+74.03% 49.64B
+1.05%+3.84%+64.12%+113.57% 36.54B
+2.06%+4.18%-6.33%+25.47% 12.22B
+2.14%-0.32%+12.85%+77.57% 11.48B
+1.05%+1.16%+31.33%+131.86% 9.04B
+0.17%-0.34%+12.61%+31.76% 6.74B
+3.53%+2.81%+4.81%+187.07% 6.45B
+0.61%-6.24%-32.70%-1.66% 5.42B
+1.62%-1.80%+20.31%+100.12% 4.37B
Average +1.60%-1.32%+17.39%+73.54% 14.88B
Weighted average by Cap. +1.25%+0.25%+26.11%+80.88%

Financials

2027 *2028 *
Net sales 454B 2.78B 2.44B 2.27B 2.09B 3.91B 265B 3.98B 26.91B 10.53B 131B 10.42B 10.19B 444B 2.72B 2.38B 2.22B 2.04B 3.83B 259B 3.89B 26.32B 10.3B 129B 10.19B 9.97B
Net income 70.98B 434M 381M 354M 326M 611M 41.43B 621M 4.2B 1.65B 20.54B 1.63B 1.59B 62.51B 382M 335M 312M 287M 538M 36.48B 547M 3.7B 1.45B 18.09B 1.43B 1.4B
Net Debt -199B -1.22B -1.07B -994M -915M -1.71B -116B -1.74B -11.8B -4.62B -57.66B -4.57B -4.47B -218B -1.33B -1.17B -1.09B -1B -1.88B -127B -1.91B -12.93B -5.06B -63.16B -5B -4.9B
Logo Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company is engaged in the manufacture and sale of prescription and over-the-counter drugs. The Company has been particularly focused on research and development of prescription drugs, positioning them as its core business. The Company’s products include injectables, oral medications, and patches.
Employees
4,206
Date Price Change Volume
26-07-29 JP¥2,491.50 +3.08% 2,326,700
26-07-28 JP¥2,417.00 -0.92% 1,462,400
26-07-27 JP¥2,439.50 +0.18% 1,568,600
26-07-24 JP¥2,435.00 +1.52% 1,507,300
26-07-23 JP¥2,398.50 -0.27% 1,081,400
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2,417.00JPY
Average target price
2,500.00JPY
Spread / Average Target
+3.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4528 Stock